Hesperetin inhibits vascular formation by suppressing of the PI3K/AKT, ERK, and p38 MAPK signaling pathways

Preventive Nutrition and Food Science

Volumn 19, Issue 4, 2014, Pages 299-306

  Kim, Gi Dae ^a  

^a Kyungnam University   (South Korea)

Author keywords

Hesperetin; HUVECs; PI3K AKT; Vascular formation

Indexed keywords

EID: 84920492129     PISSN: 22871098     EISSN: 22878602     Source Type: Journal    
DOI: 10.3746/pnf.2014.19.4.299     Document Type: Article

References (36)

1. Patan S. 2004. Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32.
2. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
3. Holderfield MT, Hughes CC. 2008. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-β in vascular morphogenesis. Circ Res 102: 637-652.
4. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
5. Ferrara N, Kerbel RS. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
6. Cristi E, Perrone G, Toscano G, Verzì A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C. 2005. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol 58: 1170-1174.
7. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. 2000. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146.
8. Meadows KN, Bryant P, Vincent PA, Pumiglia KM. 2004. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23: 192-200.
9. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278: 35501-35507.
10. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. 2006. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69: 512-519.
11. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. 2008. Targeting the PI3K - AKT - mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412.
12. Garg A, Garg S, Zaneveld LJD, Singla AK. 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15: 655-669.
13. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H, Sakata K, Matsumoto Y, Sayama Y, Mori H. 2002. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J Cancer Res Clin Oncol 128: 539-546.
14. Binnerup SJ, Sørensen J. 1992. Nitrate and nitrite microgradients in barley rhizosphere as detected by a highly sensitive denitrification bioassay. Appl Environ Microbiol 58: 2375-2380.
15. Tsuda H, Ohshima Y, Nomoto H, Fujita K, Matsuda E, Iigo M, Takasuka N, Moore MA. 2004. Cancer prevention by natural compounds. Drug Metab Pharmacokinet 19: 245-263.
16. Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH, Lee SM. 2012. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res 56: 945-956.
17. Choi EJ, Kim GD, Chee KM, Kim GH. 2006. Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. Nutrition 22: 947-951.
18. Kim GD, Kim GJ, Seok JH, Chung HM, Chee KM, Rhee GS. 2008. Differentiation of endothelial cells derived from mouse embryoid bodies: a possible in vitro vasculogenesis model. Toxicol Lett 180: 166-173.
19. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. 2008. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing VEGFR2 signaling. Cancer Res 68: 1843-1850.
20. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. 2011. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7: 89-104.
21. Tozer GM, Kanthou C, Baguley BC. 2005. Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
22. Newman DJ, Cragg GM. 2004. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67: 1216-1238.
23. Kim GD, Bae SY, Park HJ, Bae K, Lee SK. 2012. Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway. Cell Physiol Biochem 30: 758-770.
24. Kim GD, Oh J, Park HJ, Bae K, Lee SK. 2013. Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells. Int J Oncol 43: 600-610.
25. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R, Schweigerer L. 1997. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57: 2916-2921.
26. Cao Y, Cao R, Bra˚kenhielm E. 2002. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 13: 380-390.
27. Tosetti F, Ferrari N, De Flora S, Albini A. 2002. 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: 2-14.
28. Dorai T, Aggarwal BB. 2004. Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140.
29. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. 2003. Angiogenesis assays: a critical overview. Clin Chem 49: 32-40.
30. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. 2000. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 268: 183-191.
31. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. 2006. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69: 1226-1233.
32. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
33. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM. 2008. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7: 1994-2003.
34. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H, Sakata K, Matsumoto Y, Sayama Y, Mori H. 2002. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J Cancer Res Clin Oncol 128: 539-546.
35. Cross MJ, Claesson-Welsh L. 2001. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207.
36. Shiojima I, Walsh K. 2002. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250.